ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Up 47.9% in December

ABIVAX Société Anonyme (NASDAQ:ABVX) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 853,600 shares, an increase of 47.9% from the December 15th total of 577,200 shares. Approximately 1.6% of the company’s shares are short sold. Based on an average trading volume of 162,900 shares, the days-to-cover ratio is currently 5.2 days.

Analysts Set New Price Targets

ABVX has been the subject of a number of recent analyst reports. Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. JMP Securities restated a “market outperform” rating and issued a $33.00 price target on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $38.67.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ABVX. GAMMA Investing LLC bought a new stake in ABIVAX Société Anonyme in the 4th quarter valued at $29,000. BNP Paribas Financial Markets boosted its stake in shares of ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after buying an additional 5,900 shares during the period. Walleye Capital LLC lifted its position in shares of ABIVAX Société Anonyme by 45.8% during the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after acquiring an additional 80,807 shares during the period. abrdn plc raised its stake in ABIVAX Société Anonyme by 167.7% in the third quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after purchasing an additional 198,225 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its position in shares of ABIVAX Société Anonyme by 28.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after buying an additional 119,300 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors and hedge funds.

ABIVAX Société Anonyme Stock Performance

Shares of ABVX opened at $6.29 on Thursday. The company’s fifty day simple moving average is $8.22 and its 200 day simple moving average is $10.33. ABIVAX Société Anonyme has a 1-year low of $5.54 and a 1-year high of $17.02.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.